Clinical Trials in Nashville

Showing 7781-7800 of 15,379 trials

Evaluating the Safety and Drug Interaction of PA-824, an Investigational Tuberculosis Medication, Together With Efavirenz, Ritonavir-Boosted Lopinavir, or Rifampin

NCT01571414

Tuberculosis (TB) is a global public health concern and developing new treatment regimens is an important research priority. PA-824 is an experimental TB medication. This study will evaluate the safety and tolerability of PA-824 when combined with efavirenz (EFV) or ritonavir-boosted lopinavir (LPV/r), which are medications used to treat HIV infection, or rifampin (RIF), which is a medication used to treat TB. Study researchers will examine the safety and tolerability of these drug combinations and how the medications affect the levels of PA-824 in the blood.

Tuberculosis

National Institute of Allergy and Infectious Diseases (NIAID)52 participantsStarted May 2012

San Francisco, California, United States • Baltimore, Maryland, United States • Columbus, Ohio, United States +1 more locations

COMPLETEDPhase 1< 1 mile

Evaluating the Safety, Tolerability, and Effect of a Human Monoclonal Antibody (VRC01) on Markers of HIV Persistence in HIV-Infected Adults Receiving Antiretroviral Therapy (ART)

NCT02411539

The purpose of this study was to evaluate the safety, tolerability, and effect of an experimental human monoclonal antibody (mAb), VRC-HIVMAB060-00-AB (VRC01), in adults infected with HIV who were receiving antiretroviral therapy (ART).

HIV Infections

National Institute of Allergy and Infectious Diseases (NIAID)40 participantsStarted Aug 2015

San Diego, California, United States • Aurora, Colorado, United States • Chicago, Illinois, United States +10 more locations

Evaluating the Safety and Drug Interaction of PA-824, an Investigational Tuberculosis Medication, Together With Efavirenz, Ritonavir-Boosted Lopinavir, or Rifampin

Evaluating the Safety, Tolerability, and Effect of a Human Monoclonal Antibody (VRC01) on Markers of HIV Persistence in HIV-Infected Adults Receiving Antiretroviral Therapy (ART)

Find Trials by Condition in Nashville

Registrational Study With Omecamtiv Mecarbil (AMG 423) to Treat Chronic Heart Failure With Reduced Ejection Fraction

Safety of and Immune Response to the Human Papillomavirus (HPV) Vaccine in HIV-Infected Women

Effectiveness of Palifermin in Increasing CD4 Counts in Treatment-Experienced HIV Infected Adults

Optimizing Treatment for Treatment-Experienced, HIV-Infected People

Effects of a Uridine Supplement on HIV Infected Adults With Lipoatrophy

SI-613 Study for Knee Osteoarthritis

Atazanavir Used in Combination With Other Anti-HIV Drugs in HIV-Infected Infants, Children, and Adolescents

A Randomized, Comparative Study of Daily Dapsone and Daily Atovaquone for Prophylaxis Against PCP in HIV-Infected Patients Who Are Intolerant of Trimethoprim and/or Sulfonamides

Virologic Responses To New Nucleoside Regimens After Prolonged ZDV or ddI Monotherapy

Nitazoxanide Plus Ribavirin and Peginterferon for Therapy of Treatment Naive HCV Genotype 1 and HIV Coinfected Subjects

Safety of and Immune Response to a Novel Human Papillomavirus Vaccine in HIV Infected Children

Safety of and Immune Response to an H1N1 Influenza Vaccine in HIV Infected Pregnant Women

A Study of Three Drugs Plus Zidovudine in the Prevention of Infections in HIV-Infected Patients

A Multiple Dose, Dose Escalation Trial of AEB1102 in Patients With Advanced Solid Tumors

The Safety and Effectiveness of Methylprednisolone in the Treatment of Pneumocystis Carinii Pneumonia (PCP) in Children With AIDS

A Phase I Concentration-Controlled Trial to Assess the Safety, Tolerance, Pharmacokinetics and Development of Decreased HIV-1 Susceptibility to the Combination of Atevirdine Mesylate (U-87201E), Zidovudine (AZT), and Didanosine (ddI)

NOWDx Test for the Detection of Antibodies to COVID-19 in Lay Persons

Assessment of Pre-Exposure Prophylaxis (PrEP) Administered at Sexually Transmitted Disease (STD) Clinics